U.S. Markets closed

AcelRx Pharmaceuticals, Inc. (ACRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.550.00 (0.00%)
At close: 4:00PM EDT
People also watch
  • OT
    To get an idea of what a positive ADCOM opinion can look like please check out PBYI.
    It is just ADCOM opinion not FDA approval.
    Cancer vs opioid I know.
  • Could not spot any news. Why the heavy volume and big jump in PPS.
  • In the short-term ACRX does not seem to be like a good trade. check out awesom-eSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • By the time Dsuvia gets approved, we will be down to about 80 cents pps. Then it will skyrocket to 3.50. LMAO
  • This is out of hand.
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets



    Clyra Medical | Make Life Better
  • Imagen-adagio
  • Been in this company for four years now; And yes, it hasn't been the greatest experience, but newbies getting in here at $2.55 will make a killing. Foru catalysts coming up; two of them this summer: ADCOM as Pam mentioned and Zalviso data read. The other two are due near EOY: FDA on ARX-02 and NDA on ARX-04. And yes, fifth catalyst EMA decision in 2018; but by then i think this nightmare will end with Acel selling itself after getting one FDA approval...
  • Company investors are pulling out their hair? Company should be doing more to keep the stock price sane not insane like it has been for the last few months. Time for management to look at who has invested in their business - They are called investors and not people who are donating to their cause. Their progress is yes slow, but that does mean they can ignore their stock price during the run to the finish line. Give the market some actual new information about value and not the same story about how it could be a billion dollar drug company.
  • the problem is management. I can't believe that after 4 years of futility they are still waiting for results of trials. All they had to do was give Zalviso to an expert medical device maker for 30 % of sales and let them use their money to redesign the safest instrument possible.
  • with pps locked between 2.5-2.6, i guess Acel is hitting the ATM machine to beef up cash (which is not low anyway). Was their a shelf filed previously? anyone know?
  • News was as expected. Burning cash reserves while building partners.
    Momentum is going to be painfully slow until FDA approval on NDA.
    Also, European sales and approvals will progress forward just as slow.
    Their forward looking statements include the word in the future for a reason.
    I'm long on AcelRx Pharmaceuticals and believe in there products as being a good solution.
  • Zalviso trial complete, data due soon, file with FDA by end of year.
  • Did he say 40% growth in EU?
  • yea, it will be a while longer, but maybe worth the wait
  • Should I flip a coin as to if I listen to the earnings call? OR should I get drunk and drunk dial with a question?
  • Good news today! Join the AcelRx Pharmaceuticals, Inc. Earnings Conference Call this afternoon and you will be all smile for this company.
  • wozers this is a bad stock ain't it. glad I didn't not buy this one. some companies are just bad.
  • Looks like possible institutions are selling off.
  • when are they going to help this stock out , management is clueless.